Furthermore, the mechanism of expression regulation between CD58 and PD-L1 revealed that for CD58-PD-L1+ tumor cells, the strategy of co-targeting CD58 with PD-1/PD-L1 blockers may be more beneficial to activate T-cell killing, thus overcoming drug resistance in this tumor type. The gene discussed is CD274; the disease is neoplasm.